UArizona researchers have created an AI powered data-driven tool to forecast a personalized due date window for expectant mothers utilizing data from commonly worn personal devices like smart rings at various periods in gestation.

We offer a novel topical treatment for ocular degeneration that restores neuronal function and vision with a simple eye drop.

Precision anti-infective technology focused on a microbiome sparing strategy. We target Clostridioides difficile infection (CDI), an antibiotic-associated infectious diarrheal disease, through oral delivery of a targeted Antisense Oligonucleotide.

The SeVA platform is a composite AI device that can be effectively deployed in hospital, nursing homes and home settings. It has the capability to track a patient’s mental and physical state and signal early signs of risks such as delirium, falls or impending illness. It provides emotional support to the patient and their family by indulging in a natural conversation and facilitating their needs. When fully deployed, the product can serve as a platform which allays worry for people and their caregivers and will reduce healthcare costs by identifying the early signs of severe illness.

Our data-driven platform integrates high-throughput analytics and AI for next-generation drug discovery. We leverage novel insights into the foundational biologic pathways of neurodegenerative diseases to discover, evaluate, and develop disease-modifying therapeutics for Alzheimer’s disease, frontotemporal dementia (FTD) , amyotrophic lateral sclerosis (ALS), and other degenerative diseases of the nervous system.

University of Arizona researchers have developed an affordable precision brace technology for carpal tunnel relief, delivering targeted compression and customized comfort to transform hand health.

We offer a novel tool for antibiotic treatment. Our approach targets a broad spectrum of bacteria but eliminates the risk of evolving resistance by targeting a multitude of pathways.

Many cancer drugs suffer from severe adverse effects due to acute high exposure and inadequate distribution to tumors. This technology provides a vehicle for the preferred delivery of existing and approved drugs to tumor environments and local release of the active agent, thereby focusing exposure to tissues in need and reducing unwanted side effects.